Ayan Hussein

Ayan Hussein, on behalf of Kristen Kluska, asked for physician feedback on what level of transfusion reduction or independence is considered clinically meaningful for patients with lower-risk MDS.

Answer

EVP & Chief Medical Officer Lisa Rojkjaer explained that with current therapies achieving around 40% transfusion independence, a significant unmet need remains for the other 60% of patients. She stated that physicians would welcome any improvement on this rate, also noting that factors like a more convenient oral administration and a better toxicity profile represent opportunities for improvement.

Ayan Hussein, on behalf of Kristen Kluska at Cantor Fitzgerald, asked about the patient screening process for the Phase III 4WARD trial and the conversion rate from screening to enrollment.

Answer

Paula Ragan (Executive) and Christophe Arbet-Engels (Executive) stated that while specific screening metrics are not being disclosed, site activation has reached 90% of the target. They confirmed that screening is ramping up as expected and the trial is on trajectory for full enrollment in Q3 or Q4 2025.